Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.

Autor: Mort JF; Division of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, Virginia, USA., Brighton D; Department of Public Health Sciences, The University of Virginia, Charlottesville, Virginia, USA., DiBenedetto S; Division of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, Virginia, USA., Wells L; Division of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, Virginia, USA., Clark SM; Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA., Reid J; Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA., Patel I; Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA., Jackson C; Section of Hematology and Oncology, Department of Internal Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA., Yelvington B; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Miller R; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Perciavalle M; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Walsh K; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Wolfe H; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., Locke SC; Duke Cancer Institute, Durham, North Carolina, USA., Zeidner JF; Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA., Duong VH; Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA., Reed DR; Section of Hematology and Oncology, Department of Internal Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA., Dholaria B; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., LeBlanc TW; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., Keng M; Division of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, Virginia, USA., Horton B; Department of Public Health Sciences, The University of Virginia, Charlottesville, Virginia, USA., El Chaer F; Division of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, Virginia, USA.
Jazyk: angličtina
Zdroj: European journal of haematology [Eur J Haematol] 2024 Nov 27. Date of Electronic Publication: 2024 Nov 27.
DOI: 10.1111/ejh.14354
Abstrakt: Gemtuzumab ozogamicin (GO) is a CD33-targeting antibody-drug conjugate approved for the treatment of CD33-positive de novo and relapsed and refractory acute myeloid leukemia (AML). Subset analyses have demonstrated improved clinical outcomes in patients with favorable-risk disease. It is unclear whether the addition of GO to cytarabine and anthracycline chemotherapy (7+3) improves clinical outcomes compared with other conventional regimens for AML. We evaluated the real-world experience with GO added to 7+3 chemotherapy for patients with favorable risk AML. This retrospective analysis included 174 patients with de novo favorable risk AML undergoing induction chemotherapy between 2010 and 2020. The primary outcome was overall survival (OS) and secondary outcomes included rates of remission, measurable residual disease (MRD), and toxicity. Eighteen patients received GO, 37 received a high-dose (HD) anthracycline, and 119 received an intermediate-dose anthracycline. Composite complete remission was achieved in 162 patients (93.1%). Among the 54 patients who were assessed for MRD at remission, 66.7% were undetectable. An improvement in OS was seen for patients who received GO and those treated with HD anthracycline, which was better explained by differences in patient performance status and comorbidities. Patients who received GO did not show increased toxicity.
(© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: